Immunomodulatory and Antioxidant Activity of Gouqi Chewable Tablets / 中国实验方剂学杂志

ObjectiveTo explore the regulatory effect of Gouqi chewable tablets on innate and adaptive immunity in normal mice and its antioxidant activity in vitro and in vivo. MethodThe effects of low-， medium-， and high-dose groups （0.25， 0.5， 1.5 g·kg-1） on the immune function of normal mice were observed by carbon clearance test， immune organ index test， serum hemolysin test， ConA-induced splenic lymphocyte proliferation test， and natural killer cell （NK cell） activity test. The effects of Gouqi chewable tablets on the antioxidant capacity in vivo were determined by detecting the content of superoxide dismutase （SOD）， glutathione peroxidase （GSH-Px）， and malondialdehyde （MDA） in mice serum. The in vitro antioxidant activity of Gouqi chewable tablets was detected by 2，2'-azino-bis（3-ethylbenzothiazoline-6-sulfonic acid） diammonium salt （ABTS）， 2，2-diphenyl-1-picrylhydrazyl （DPPH）， and hydroxyl radical scavenging tests. ResultCompared with the blank control group， the low-， medium-， and high-dose groups of Gouqi chewable tablets improved the viability of NK cells， the proliferation of splenic lymphocytes， and the level of serum hemolysin antibody in mice （P<0.05）. The high-dose group increased the thymus index， spleen index， and phagocytic function of macrophages （P<0.05， P<0.01）. As compared with the blank control group， the activity of GSH-Px in mice serum in the medium-dose group was increased （P<0.05）， and the content of MDA in mice serum in the high-dose group was decreased （P<0.05）. In in vitro antioxidant tests， the median inhibitory concentration （IC50） values of Gouqi chewable tablets were 1.64±0.20， 2.04±0.03， and 10.27±0.03 g·L-1 by the DPPH， ABTS， and OH- free radical method， respectively. Those results indicated that Gouqi chewable tablets have good antioxidant effects in vitro. ConclusionGouqi chewable tablets can enhance the immune function of mice with good antioxidant effects.

Clinical study on Jiedu-Huaban Decoction combined with montelukast sodium chewable tablets in the treatment of children with Henoch Schonlein purpura and blood heat syndrome / 国际中医中药杂志

Objective:To evaluate the efficacy of Jiedu-Huaban Decoction combined with montelukast sodium chewable tablets in the treatment of children with henoch schonlein purpura (HSP). Methods:A total of 80 children with HSP and blood heat syndrome who met the inclusion criteria, from January 2017 to December 2019, were randomly divided into two groups by random number table method, 40 in each group. The control group took montelukast sodium chewable tablets at night, and the study group took Jiedu-Huaban Decoction on the basis of the control group. Both groups were treated for 2 weeks. The disappearance time of gastrointestinal disease, skin purpura, kidney disease, joint swelling and pain were observed. The improvement score of skin purpura was evaluated before and after treatment. The serum levels of IL-6, IL-4, interferon-γ (IFN-γ) and TNF-α were detected by ELISA, and the levels of IgG, IgA and IgM. The T lymphocyte subsets (CD4 + and CD8 +) were measured by nephelometry, and the CD4 +/CD8 +values were calculated. The clinical efficacy was evaluated. Results:The total effective rate was 87.5% (35/40) in the study group and 67.5% (27/40) in the control group, with significant difference between the two groups ( χ2 =4.588, P=0.032). The disappearance time of gastrointestinal disease, skin purpura, kidney disease and joint swelling and pain in the study group were significantly earlier than those in the control group ( t=7.802, 12.167, 7.309, 9.365, all Ps<0.001). After treatment, the serum levels of IL-6, IL-4, IFN-γ and TNF-α in the study group were significantly lower than those in the control group ( t=9.319, 6.738, 8.221, 6.553, all Ps<0.001). The improvement score of skin purpura at 1 week after treatment (2.75 ± 0.69 vs. 3.92 ± 0.83, t=6.856) and 2 weeks after treatment (0.41 ± 0.15 vs. 1.55 ± 0.37, t=18.095) in the study group were significantly lower than those in the control group ( P<0.01). After treatment, the level of IgG, CD4 +, CD4 +/CD8 + in the study group were significantly higher than those in the control group ( t=5.160, 4.558, 3.442, all Ps<0.01), the level of IgA, IgM, CD8 + in the study group were significantly lower than those in the control group ( t=2.614, 6.712, 5.468, all Ps< 0.05). During the treatment, the incidence of adverse reactions in the control group was 17.5% (7/40), and that of the study group was 15.0% (6/40), wherer there was no statistical difference between the two groups ( χ2=0.092, P=0.762). Conclusion:Jiedu-Huaban Decoction combined with montelukast sodium chewable tablets can improve the clinical symptoms of children with HSP and blood heat syndrome, reduce the body inflammatory reaction, improve immunity, with good safety.

Preparation of compound Shenzao chewable tablets and determination of spinosin content / 国际药学研究杂志

Objective: To optimize the formulation and preparation process of compound Shenzao chewable tablets, and establish a method for the determination of the active ingredient spinosin. Methods: Using the wet granulation process, the types, dosages and adding manners of diluents, wetting agents, sweeteners and lubricants were optimized, and three batches of the compound Shenzao chewable tablets were prepared. An HPLC method for the determination of spinosin in the tablets was established and the HPLC conditions were as follows: ZORBAX SB-C 18 column(4.6 mm×250 mm, 5 μm)was adopted. The mobile phase was the acetonitrile-water solution in a gradient elution. The flow rate was 1.0 ml/min, the column temperature was 25℃ and the detection wavelength was 335 nm. Results: In the wet granulation process, the dry Lepidium meyenii (Maca)powder and 20% mannitol were used as diluents, the 80% ethanol as wetting agent, and the 0.50% aspartame as sweetener. In the tabletting process, the 1.0% magnesium stearate was used as lubricant. The prepared tablets showed smooth surface, moderate sweetness, and a stable and controllable quality. The HPLC method for the determination of spinosin showed a good linearity within the concentration range of 5~100 μg/ml (r=0.9995)and the average recovery was 98.55%. Conclusion: The optimized formulation and preparation process are stable and feasible for the preparation of the compound Shenzao chewable tablets. The determination of spinosin by the HPLC method is accurate and reliable, which might be used for the quality control of the preparation.

Clinical study of the Liangxue-Zhuyu decoction combined with montelukast in the treatment of henoch schonlein purpura / 国际中医中药杂志

Objective To study the efficacy of Liangxue-Zhuyu decoction combined with montelukast in the treatment of henoch schonlein purpura (HSP) and its influence on immunologic function. Methods A total of 95 HSP children treated in department of pediatrics from February 2014 to December 2016 were enrolled, and then were randomly divided into observation group (n=48) and control group (n=47), meanwhile another 48 healthy children admitted to a medical examination were selected as the healthy group. The patients in the control group were given the treatment of oral montelukast sodium chewable tablets before sleeping (the dose:2-6 years old 4 mg/d, 6-14 years old 5 mg/d), and the patients in the observation group accepted the therapy of Liangxue-Zhuyu decoction based on the treatment of the control group.The course of the treatment in the two groups were 30d. The time of clinical symptom regression and adverse reactions were recorded, and the clinical efficacy was evaluated. Monoclonal antibody immunofluorescence method and Enzyme-linked immunosorbent assay (ELISA) were used to detect the levels of serum T lymphocyte subsets and INF-γ and IL-10 before and after treatment, and their differences among three groups were compared. Results The effective rates of the observation group was 95.8% (46/48), which was significantly higher than 76.6% (36/47) of control group (x 2=7.441,P<0.05).The subsided time of the symptoms,including purpura(5.0 ± 1.3 d vs.6.6 ± 2.6 d,t=3.816), abdominal pain(3.1 ± 2.1 d vs.4.1 ± 2.6 d,t=2.139),joint pain(4.3 ± 1.5 d vs.5.4 ± 1.9 d,t=3.416),fecal occult blood(4.5 ± 1.5 d vs.6.1 ± 1.9 d,t=4.404)of the observation group were significantly shorter than those of the control group(P<0.05).After the treatment,the CD4(45.14% ± 9.32% vs.41.02% ± 9.97%),CD8(25.10% ± 4.69% vs.21.52% ± 5.71%)of the observation group was significantly higher than those of the control group, and the CD4/CD8(1.62 ± 0.32 vs.1.95 ± 0.35)and IL-10(33.07 ± 1.86 pg/ml vs.53.92 ± 2.98 pg/ml)of the observation group was significantly lower than this of the control group (P<0.05). Conclusions The efficacy of the Liangxue-Zhuyu decoction combined with montelukast for HSP was definite,and the effect was rapid with little side effects. The mechanism might be related to regulating the secretion of T lymphocyte and IL-10, thereby to correct Th1/Th2 cell balance and disturbance of immune function.

Simultaneous Determination of 4 Active Components in Compound Xiaosuanzao Chewable Tablets by HPLC-ELSD / 中国药房

OBJECTIVE:To establish the method for the content determination of 4 active components in Compound xiaosuanzao chewable tablets.METHODS:HPLC-ELSD method was adopted.The determination was performed on a Grace Brava C18-BDS column with mobile phase consisted of acetonitrile-water (gradient elution) at the flow rate of 1.0 mL/min.The column temperature was 25 ℃,and sample size was 20 μL.The drift tube temperature is 100 ℃,and the carrier gas flow rate is 2.9 L/min.RESULTS:The linear ranges of betulic acid,betulinol,pachymic acid and glycyrrhizic acid were 44.50-890.0 μg/mL (r=0.999 3),20.28-405.6 μg/mL (r=0.999 7),20.50-656.0 μg/mL(r=0.999 7) and 10.50-336.0 μg/mL(r=0.999 6),respectively.RSDs of precision,stability and reproducibility were all lower than 3.0％.The recoveries were 99.44％-101.12％ (RSD=0.57％,n=6),99.41％-100.39％ (RSD=0.34％,n=6),99.31％-100.46％ (RSD=0.51％,n=6),98.96％-101.19％ (RSD=0.84％,n=6),respectively.CONCLUSIONS:The method is simple,precise,stable and reproducible,and can be used for simultaneous determination of 4 active components in Compound xiaosuanzao chewable tablets.

Effects of montelukast sodium chewable tablets on the tonsils and adenoids in children with OSAHS / 中国生化药物杂志

Objective To study the montelukast sodium chewable tablets for the treatment of obstructive sleep apnea hypopnea syndrome(OSAHS)patients and treatment of tonsil and adenoid effect.Methods 84 cases of OSAHS patients in our hospital from January 2014 to August 2016 were randomly divided into the observation group and the control group,42 cases in each group.The control group was treated with conventional symptomatic treatment,on this basis,the patients in the observation group received montelukast sodium chewable tablets treatment,compared the two groups of the total efficiency,and compared before and after treatment of symptoms total score,apnea hypopneaIndex(AHI),the lowest arterial oxygen saturation(LSaO2),and adenoid and tonsil classification indexing.Results the total efficiency of observation group(90.48％)was significantly higher than the control group(69.04％,χ2=5.97,P<0.05); after treatment,the observation group of the total symptom score and AHI were significantly lower than the control group(P<0.05),LSaO2 was significantly higher than the control group(P<0.05),adenoid grade one and grade two were significantly higher than the control group(χ2=9.82,P<0.05),there was no significant difference between the one and two degrees of tonsil dividing ratio.Conclusion The clinical efficacy of montelukast sodium chewable tablets in the treatment of children with OSAHS is significant,can effectively reduce the volume of tonsil and adenoid body,and improve the clinical symptoms and sleep treatment significantly,which is worthy of clinical promotion.

Pharmacological Effect of Leshibao Chewable Tablets in Young Anorexia Rats / 中国药师

Objective:To study the pharmacological effects of Leshibao chewable tablets for juvenile rats with anorexia. Methods:The rats were divided into 6 groups with 10 ones in each and fed with special forage for 4 weeks to establish the anorexia model of ju-venile rats. After the model establishment, from the 8th day, the treatment groups received Leshibao chewable tablets respectively at the dose of 0. 60, 0. 30 and 0. 15 g·kg-1 ·d-1 for three weeks. The general situation was observed, and the appetite and body weight were recorded during the treatment. At the end of experiment, the gastric juice amount, free gastric acidity, total gastric acidity and pepsin activity were determined, TP, ALB, TCHO, MTL and GAS were determined by kit methods. Additionally, the mice were given Leshibao chewable tablets at different doses (0. 80, 0. 40, 0. 20 g·kg-1 ·d-1 ) for 7 days, the effects of Leshibao chewable tablets on gastric emptying and intestinal propulsive function were observed. Results: Leshibao chewable tablets could significantly increase the body weight, appetite (P<0. 05 or P<0. 01), gastric juice amount, free gastric acidity , total gastric acidity and pepsin secretion (P<0. 05 or P<0. 01), significantly reduce TP, ALB and TCHO in serum (P<0. 05 or P<0. 01), significantly increase MTL and GAS contents (P<0. 05 or P<0. 01), and significantly promote gastric emptying and intestinal propulsion in mice (P<0. 05 or P<0. 01). Conclusion:Leshibao chewable tablets can significantly increase body weight and appetite, and improve digestive function re-markably, which exhibit excellent therapeutic effect in the anorexia model of juvenile rats.

Preparation and Stability of Levocetirizine Hydrochloride Chewable Tablets / 中国药房

OBJECTIVE:To prepare Levocetirizine hydrochloride chewable tablets,and to investigate the stability. METH-ODS:Levocetirizine hydrochloride chewable tablets were prepared with wet granulation. Using accumulative dissolution rate within 45 min as index,the formulation of Levocetirizine hydrochloride chewable tablets was optimized by orthogonal design with the in-ternal and external ratio of MCC and carboxymethyl starch sodium,the amount of magnesium stearate as factors. The dissolution rate and content uniformity of optimized tablet were verified. The appearance,dissolution rate,related substance and content change of the tablet were investigated within 10 d under the condition of high temperature(60 ℃),high light(4 500 lx)and high moisture (92.5%). RESULTS:The optimized formulation of the tablet was as levocetirizine hydrochloride 5 mg,lactose 30 mg, microcrystalline cellulose 90 mg(internal-external ratio 4∶5),mannitol 60 mg,aspartame 10 mg,carboxymethyl starch sodium 12 mg(internal-external ratio 1∶1)and magnesium stearate 1.0%. The accumulative dissolution rates of 3 batches of optimized tablet were(97.23±1.21)%,(98.49±1.28)% and(98.15±1.94)%. The content uniformity were 2.30,2.34 and 2.60. Those indicators had no significant change except related substance increased slightly under high temperature on 10th day and high moisture on 5th day. CONCLUSIONS:Levocetirizine hydrochloride chewable tablets is prepared successfully with good stability.

Optimization of the Extraction Technology of Compound Epimedium Chewable Tablets by Orthogonal Test / 中国药房

OBJECTIVE:To optimize the extraction technology of Compound epimedium chewable tablets. METHODS:Using the extraction rate of icariin,the content of crude polysaccharide and yield of extractum as index,the effects of water amount,ex-traction time and extraction times on extraction effect were investigated by orthogonal test. The extraction technology was optimized and validation test was conducted. RESULTS:The optimized extraction technology was as follows as 6-fold water,extracting 3 times,2 h each time. The validation test showed that the average extraction rate of icariin was(83.80±0.02)%,the average con-tent of crude polysaccharide was (29.28 ± 0.55) mg/g,and the average yield of extractum was (28.47 ± 0.29)%(RSD≤0.55%, n=3). CONCLUSIONS:The optimized extraction technology is stable,and can be used for the extraction of Compound epimedi-um chewable tablets.

Content Determination of Vitamin B1 and Vitamin B2 in Trivitamin and Calcium Gluconate,Calcium Hydro-gen Phosphate Chewable Tablets by HPLC / 中国药房

OBJECTIVE:To establish a method for the content determination of vitamin B1 and vitamin B2 in Trivitamin and calci-um gluconate,calcium hydrogen phosphate chewable tablets. METHODS:HPLC was conducted. The column was Inertsil C18 with the mobile phase of 1%triethylamine contained 0.02 mol/L of sodium heptane solution(pH was adjusted to 5.5 by phosphate)-methanol (74∶26,V/V)at the flow rate of 1.0 ml/min,the detection wavelength was 260 nm,temperature was 30℃and the volume was 20μl. RESULTS:There was a good linear relationship between the quality concentration of vitamin B1 and peak area in the range of 0.22-1.10μg/ml(r=0.999 8)and vitamin B2 was in the range of 0.22-1.09μg/ml(r=0.999 7). The RSDs of precision,reproducibility and stabil-ity tests were all less than 1%;the average recovery was respectively 99.66%(RSD=0.96%,n=9)and 100.31%(RSD=0.92%,n=9). CONCLUSIONS:The method is simple,accurate,sensitive and reliable and suitable for the content determination of vitamin B1 and vitamin B2 in Trivitamin and calcium gluconate,calcium hydrogen phosphate chewable tablets.

Determination of content and related substances of caffeine chewable tablets by HPLC / 国际药学研究杂志

Objective: To establish a method for determination of the content and related substances in caffeine chewable tablets. Methods: Agilent TC - C18 column (250 mm×4.6 mm; 5μm) was used. The mobile phase was methanol-sodium dihydrogen phosphate buffer solution(10mmol/L, adjusted to pH 3.0 with phosphoric acid ) (75:25, V/V), with a flow rate 1.0 ml/min, and the detection wavelength was 273 nm. The column temperature was 30℃ and the injection volume was 20 μl. Results: The calibration curves showed good linearity(r=1, n=7) within ranges of 1-400 μg/ml. The average recovery of the method was about 100.04%(RSD=0.12%, n=9), and the stability of working solutions was acceptable in 24 h (RSD=1.07%, n=8). Conclusion: The results indicated that the developed method could be readily utilized as a method for the quality control, including contents determination, intermediate products and stability study.

Determination of content and related substances of caffeine chewable tablets by HPLC / 国际药学研究杂志

Objective To establish a method for determination of the content and related substances in caffeine chewable tablets. Methods Agilent TC - C18 column(250 mm×4.6 mm;5μm)was used. The mobile phase was methanol- sodium dihydrogen phosphate buffer solution(10mmol/L,adjusted to pH 3.0 with phosphoric acid )(75:25,V/V),with a flow rate 1.0 ml/min,and the detection wavelength was 273 nm. The column temperature was 30℃ and the injection volume was 20 μl. Results The calibration curves showed good linearity(r=1,n=7)within ranges of 1-400 μg/ml. The average recovery of the method was about 100.04%(RSD=0.12%,n=9),and the stability of working solutions was acceptable in 24 h (RSD=1.07%,n=8). Conclusion The results indicated that the developed method could be readily utilized as a method for the quality control,including contents determination, intermediate products and stability study.

Aplicación de la calidad basada en el diseño (QbD) en la reformulación de tabletas masticables / Application of Quality by Design (QbD) to reformulation of chewable tablets

El presente trabajo ilustra la implementación de los principios de la calidad basada en el diseño (QbD) en la fabricación industrial de medicamentos. Como caso de estudio se eligió la elaboración de tabletas masticables, cuya formulación y proceso de manufactura se rediseñaron. Se tomó como punto de partida la definición del perfil de calidad para el producto, el que sirvió de base para identificar los atributos críticos de calidad. Posteriormente, se analizó el impacto y la criticidad de cada una de las operaciones de fabricación en la calidad del producto, y para cada una de las operaciones que resultaron críticas, se realizó el análisis de riesgos. De acuerdo con los resultados obtenidos, se diseñaron e implementaron las estrategias de mitigación, logrando una formulación acorde con las expectativas desde el punto de vista organoléptico y la reducción en un 25% de los tiempos de producción.

This research work illustrates the implementation of Quality by Design (QbD) principles into pharmaceutical industry. The manufacture of chewable tablets was chosen as case study. In this way, product formulation and preparation procedure were reformulated. The starting point was the definition of the product quality profile from which the critical quality attributes were identified. Also, the impact and the criticality of each stage of manufacture for the product were examined regarding to their influence in achieving the critical quality attributes. Risk assessment was made for critical manufacture stages and considering the results, mitigation strategies were proposed and implemented. This leads to a formulation satisfying the requirements for the organoleptic properties like the 25% reduction in the production time.

Evaluation of hydrotalcite in treatment of functional dyspepsia epigastric pain syndrome: a multicenter randomized open positive controlled clinical trial / 中华消化杂志

Objective To evaluate the clinical efficacy and safety of hydrotalcite chewable tablets in treatment of patients with functional dyspepsia epigastric pain syndrome(EPS), and to investigate the onset time of hydrotalcite after the first dosage and whether use of hydrotalcite in EPS is a costeffective strategy. Methods A multicenter, randomized, open, positive controlled clinical trial was carried out in 240 patients with EPS. The subjects randomly received eigher hydrotalcite or omeprazole for 2 weeks. The improvemcnt and the disappear time of symptoms were evaluated before and after treatment and cost-effective was analyzed between two groups. Results It was demonstrated that both hydrotalcite and omeprazole could relief symptoms after treatment. After treatment for 2 weeks, the total effective rate was 85. 71% in hydrotalcite group and 90. 43% in omeprazole group with no significant difference (P＞0.05). The median onset time of hydrotalcite after first dosage was 0.417 h. The overall direct cost per patient was RMB ￥122. 29 for hydrotalcite treatment and RMB ￥242.95 for omeprazole treatment. The main adverse events included diarrhea, thirst, bloating,headache and belching. No severe adverse event was found in two groups. Conclusions Hydrotalcite has fast effect on relief of EPS symptoms. Use of hydrotalcite is a cost-effective strategy in the management of EPS. It is a safe and effective medicine in treatment of EPS.

Desenvolvimento e avaliação de formas farmacêuticas sólidas contendo didanosina / Development and evaluationof solid dosage forms with didanosine

A Síndrome da Imunodeficiência adquirida (AIDS) é uma doença de amplo espectro de manifestações, sendo razão de preocupação para qualquer autoridade sanitária. A terapêutica da AIDS é complexa sendo utilizados vários medicamentos, diversas vezes ao dia. Deste modo, objetivou-se o desenvolvimento de formas farmacêuticas sólidas como comprimidos tamponados mastigáveis (CTM), comprimidos com revestimento gastro-resistentes (CRGR) e pellets (PEL) para a veiculação de didanosina (ddl). Seis especialidades farmacêuticas na forma de CTM forma estudadas quanto ao perfil de dissolução, pH do meio e capacidade neutralizante ácida (CNA). Formulações teste de CTM foram propostas visando obter CNAs e perfis de dissolução adequados. Também foram testadas formulações de comprimidos e de pellets para posterior revestimento com filme gastro-resistente derivado do ácido metacrílico. Os ensaios de dissolução das amostras de CTM revelaram diferenças nas características de liberação do fármaco. Também foram observadas diferenças relacionadas a CNA. As formulações de CTM propostas apresentaram, na maioria dos casos, adequados perfis de dissolução e CNA. As formulações CRGR que receberam revestimento gastro-resistente apresentaram perfis de dissolução de ddl adequados, entretanto os comprimidos testados intumesceram em meio ácido, indicando descontinuidade do filme polimérico sobre os comprimidos. Testes para a produção de pellets veiculando ddl mostraram-se adequados quanto à morfologia e dissolução do fármaco, o mesmo sendo observado após o revestimento com filme gastro-resistente

The Acquired Immune Deficiency Syndrome (AIDS) is a disease that manifests itself in a myriad of ways. Because of this, the condition has been subject of concern to all sanitary authorities. The treatment of AIDS is complex and many types of medicine are used, many times a day. The objective of the present study was to develop solid pharmaceutical dosage forms such as buffered chewable tablets (CTM), gastro-resistant coating tablets (CRGR) and pellets (PEL) for the loading of didanosine (ddl). Six pharmaceutical specialties in the form of CTM were studied so as to identify the profile of the dissolution, the pH of the environment, and the neutralizing acid capacity (CNA). The use of CTM tests formulations was proposed with the objective of obtaining adequate CNA and dissolution profiles. Different compositions of tablets and pellets were tested for a later addition of gastro-resistant film derived from the methacrylic acid. The experiments on the dissolution of the sample of CTM showed differences in the characteristic of the release of the substance. Differences related to the CNA were also observed. The formulations of the CTM proposed showed to have, in the most number of the cases, both adequate dissolution behavior and CNA. The formulations of the CRGR that had received the gastro-resistant coating showed adequate profile of ddl dissolution; the tested tablets, however, swelled in the acid environment, therefore indicating a lack of continuity of the polymeric film over the tablets. The tests for the production of pellets showed adequate results as to its morphology and dissolution of ddl. The same was observed after coating the pellets with gastro-resistant film.

The dangers of enterobiasis: treatment with thiabendazole chewable tablets

The incidence of Enterobiasis particularly in the Philippines has been reviewed. The hazards of Enterobiasis particularly in females has been emphasized. The different drugs used for the treatment of Enterobiasis have also been reviewed. Twenty nine out of 33 cases of Enterobiasis were found to be negative by Scotch Tape Swab technic for pinworm eggs on or about the 12th day after treatment with Thiabendazole Chewable tablets at a dose of 25 mg./kg. body weight. On or about the 21th day and the 36th day after treatment, all the 33 cases treated were all negative for pinworm eggs by the same technic of diagnosis. It appears that Thiabendazole Chewable tablets is as efficient and convenient to use as Pyrivinium pamoate with the added advantage that it can be used in the presence of Ascaris lumbricoides because of its broad spectrum anthelmintic properties. Pyrivinium pamoate is indicated only against Enterobius. The broad specturm anthelmintic property of Thiabendazole makes it the ideal anthelmintic to use in the tropics where multiple infection with intestinal parasites is the rule.(Summary and Conclusions)